NVCT
Nuvectis Pharma, Inc.7.69
+0.04+0.52%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
196.98MP/E (TTM)
-Basic EPS (TTM)
-1.37Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Nuvectis Pharma reported a Q2 net loss of $6.3 million, up 43% year-over-year from $4.4 million, driven by higher research and development expenses of $3.6 million (up 23%) from clinical trial costs for NXP900 and NXP800, and general and administrative costs of $3.0 million (up 75%) tied to public company expenses including stock-based compensation. Operating loss widened to $6.6 million, with net loss per share at $0.30 on 21.4 million diluted shares, reflecting anti-dilution from unvested RSAs. Cash reached $26.8 million after a February public offering netting $14.0 million, funding operations for at least 12 months; free cash flow not disclosed in the 10-Q. No debt or M&A events noted. Clinical progress includes NXP900 Phase 1a showing 90% SRC inhibition at higher doses with mild GI side effects, but NXP800 Phase 1b in ovarian cancer yielded limited efficacy, prompting a pivot to other indications. Yet clinical setbacks loom large.
8-K
NXP900 advances to Phase 1b
Nuvectis Pharma elevated NXP900 to lead candidate after completing its Phase 1a dose escalation in advanced solid tumors and drug-drug interaction study, paving the way for imminent Phase 1b initiation. Cash swelled to $26.8 million at June 30, 2025, bolstered by a July ATM share sale to hit ~$39 million pro forma, funding operations into late 2027 despite a $6.3 million Q2 net loss from ramped R&D. NXP800 eyes endometrial and prostate cancers next. Momentum builds.
8-K
Annual meeting results approved
Nuvectis Pharma held its 2025 Annual Meeting on June 12, with 61.86% of shares present. Shareholders elected James Oliviero as Class III director until 2028, securing 9.9 million votes for amid minimal opposition. They also ratified Kesselman & Kesselman as auditors for the year ending December 31, 2025, with overwhelming 14.6 million votes in favor. All proposals passed smoothly.
8-K
New $60M ATM offering launched
Nuvectis Pharma launched a new $60 million at-the-market equity offering on May 9, 2025, via Leerink Partners, replacing a prior $40 million program with H.C. Wainwright that raised $18.6 million before termination. This move bolsters the biotech's cash position for clinical development, yet dilutes existing shareholders. No sales yet.
8-K
Q1 loss widens on R&D push
Nuvectis Pharma reported Q1 2025 net loss of $5.3 million, up from $4.2 million year-over-year, driven by higher R&D expenses of $3.7 million amid advancing NXP900 and NXP800 trials. Phase 1a data for NXP900 at AACR showed robust pharmacodynamic response and acceptable safety, bolstering its path to Phase 1b in targeted cancers. A $15.5 million financing boosted cash to $29.9 million, extending runway into Q1 2027. Clinical progress fuels oncology pipeline momentum.
CNTA
Centessa Pharmaceuticals plc
25.72-0.43
NBTX
Nanobiotix S.A.
22.32+0.18
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NUVB
Nuvation Bio Inc.
8.66+0.15
NUVL
Nuvalent, Inc.
102.63-2.34
NVAX
Novavax, Inc.
6.54-0.04
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
RNXT
RenovoRx, Inc.
0.84-0.10
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02